

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, February 16, 2022 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Jordan Storhaug, Committee Chair
9:05 a.m.	P&T and DUR process overview	Donna Sullivan, HCA
9:20 a.m.	Atopic dermatitis- report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Wesley Lindsey, DERP
10:35 a.m.	Break (10 min)	All
10:45 a.m.	Biologics for non-asthma conditions- report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Courtney Gamston, DERP
12 p.m.	Second generation antipsychotics- surveillance <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Roz Kelly, DERP
12:20 p.m.	Lunch (30 min)	All
12:50 p.m.	ADHD- report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Shannon Robalino, DERP & Andrea Vintro, DERP
2 p.m.	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Jordan Storhaug, Committee Chair
2 p.m.	Antibiotics <ul style="list-style-type: none"> • Aminoglycosides - Inhaled • Monobactams - Inhaled Respiratory Agents : Cystic Fibrosis Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
2:20 p.m.	Anticoagulants : Factor XA And Thrombin Inhibitors - Oral <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
2:40 p.m.	Break (10 min)	All
2:50 p.m.	Antidiabetics <ul style="list-style-type: none"> • Amylin Analogs 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • DPP4 Inhibitor / SGLT2 Inhibitor Combinations • DPP4 Inhibitor / TZD Combinations • DPP4 Inhibitors • GLP1 Agonist / Insulin Combinations • GLP1 Agonists • Insulin - Intermediate Acting • Insulin - Long Acting • Insulin - Pre-Mixed • Insulin - Rapid Acting • Short Acting • SGLT2 Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
3:25 p.m.	<p>Endocrine and Metabolic Agents</p> <ul style="list-style-type: none"> • Growth Hormone Releasing Hormones (GHRH) • Growth Hormones <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
3:40 p.m.	<ul style="list-style-type: none"> • DUR Board Adjourns 	Jordan Storhaug, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPolicy@hca.wa.gov

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.